Table 3.

Univariate analysis for association between the MMP-12 rs2276109 polymorphism and SSc clinical subsets according to recessive, dominant, and additive genetic models. Healthy controls were used as reference for all comparisons except anti-topo I-positive SSc versus anti-topo I-negative SSc, and SSc-ILD versus SSc-non-ILD.

Recessive ModelDominant ModelAdditive Model
OR (95% CI)pOR (95% CI)pOR (95% CI)p
Univariate Analysis
  SSc2.26 (1.51–3.39)< 0.00011.34 (0.42–4.28)0.61.65 (0.52–5.31)0.4
  dcSSc5.06 (2.51–10.18)< 0.00011.28 (0.28–5.92)0.71.68 (0.36–7.83)0.5
  lcSSc1.53 (0.98–2.39)0.061.19 (0.32–4.49)0.81.22 (0.32–4.60)0.8
  Anti-topo I-positive SSc6.22 (2.15–18.03)0.00021.79 (0.20–16.36)0.62.26 (0.25–20.63)0.5
  SSc-ILD2.91 (1.24–6.83)0.010.62 (0.10–3.81)0.60.74 (0.12–4.56)0.7
Multivariate Analysis*
  SSc2.44 (1.61–3.71)< 0.0001
  dcSSc4.69 (2.36–9.33)< 0.0001
  Anti-topo I-positive SSc6.39 (2.18–18.76)0.001
  SSc-ILD2.94 (1.25–6.95)0.01
  • * Adjusted for age and sex. Anti-topo I: anti-topoisomerase I antibodies; dcSSc: diffuse cutaneous SSc; ILD: interstitial lung disease; lcSSc: limited cutaneous SSc.